The Silent Threat To Clinical Trials: Why Shelf-Life Management Can Determine Study Success

By Joseph G. Oberlander, Ph.D., PMP, pharmaceutical development consultant and program manager

When most clinical trial teams discuss risk, the conversation typically centers on patient recruitment, site activation, manufacturing timelines, regulatory approvals, or funding. Yet one of the most significant and frequently underestimated threats to study execution is clinical trial material shelf-life. For clinical supply professionals, shelf-life is not simply an expiration date appearing on a label. It is a continuously diminishing asset that influences virtually every aspect of a study, from patient dosing and site operations to regulatory compliance and budget management.

The challenge is that shelf-life rarely attracts attention until it becomes a problem. Unlike a manufacturing deviation or a missed regulatory milestone, shelf-life issues develop gradually and often remain invisible until the available inventory can no longer support patient treatment. A study may appear to have ample supplies in depots and at clinical sites, but if those supplies lack sufficient remaining dating to support future dispensing, the inventory may effectively be unusable. By the time the issue becomes apparent, options are often limited, expensive, and disruptive. This reality is particularly important for small and emerging biopharmaceutical companies; many rely on a limited number of manufacturing campaigns, constrained development budgets, outsourced supply chain partners, and lean clinical supply organizations. Unlike large pharmaceutical companies that can often absorb operational setbacks through additional manufacturing capacity or large safety stocks, smaller sponsors may have few alternatives available when inventory approaches expiration. A shelf-life problem that might be manageable for a large organization can become a critical business risk for a small sponsor.

Traditionally, shelf-life has been viewed primarily as a quality or CMC responsibility. Stability scientists generate data, quality organizations establish expiration dates, and the resulting shelf-life is assigned to clinical inventory. However, this perspective overlooks the operational reality of modern clinical trials. Shelf-life affects inventory planning, packaging strategy, country activation schedules, regulatory submissions, depot operations, site management, forecasting, and patient treatment continuity. In practice, shelf-life is a cross-functional risk that must be actively managed throughout the life of a study. The distinction between theoretical shelf-life and operational shelf-life is where many organizations encounter difficulties.

Consider a clinical batch with a 24-month shelf-life: At first glance, this may appear more than adequate for a Phase 2 or Phase 3 study. However, several months may be consumed by manufacturing, release testing, packaging, labeling, and regulatory preparation before the product is ready for shipment. Additional time may be required for depot stocking, site activation, and patient enrollment. By the time the first patient receives treatment, a significant portion of the original shelf-life may already be gone. If patients are expected to remain on treatment for an extended period, inventory that technically remains within date today may not provide adequate dating to support future scheduled visits. As a result, the most important question is not, "When does this product expire?" Rather, clinical supply teams should ask, "Will this inventory remain eligible for dispensing throughout the patient's treatment period?" This subtle difference fundamentally changes how shelf-life should be managed.

When Shelf Life Becomes An Operational Constraint

The risks become substantially greater when studies move beyond the United States into multiple international markets. In a U.S.-only trial, the supply network is relatively straightforward. Product can often be distributed through a single packaging site and central depot. Regulatory expectations are generally consistent, shipping timelines are predictable, and customs clearance is not required. While logistical challenges still exist, the supply chain remains comparatively manageable. Global studies operate in an entirely different environment. Every additional country introduces new variables that consume time and increase risk. Different regulatory agencies may have distinct requirements for labeling, expiration dating, importation documentation, and implementation of shelf-life extensions. Local language requirements may necessitate complex label configurations. Multiple depots may be needed to support regional distribution. Customs inspections, import licenses, and country-specific release activities can create delays that are difficult to predict and even harder to control. Most importantly, every additional day spent navigating these processes consumes valuable shelf-life. Inventory that appears acceptable when it leaves a central warehouse may no longer have sufficient remaining dating by the time it arrives at an international clinical site. In some cases, country-specific requirements regarding minimum remaining shelf-life may prevent inventory from being imported altogether. Sponsors may find themselves with adequate global inventory but an inability to place that inventory where it is needed most.

The consequences of poor shelf-life management extend far beyond inventory waste. Patients may experience interrupted treatment if replacement supplies cannot be delivered in time. Sites may suspend enrollment when available inventory can no longer be dispensed. Emergency manufacturing campaigns may need to be initiated to replace expiring material. Relabeling activities may become necessary across multiple depots and countries. Expedited shipping, additional packaging runs, and unplanned regulatory activities can quickly escalate costs. In severe cases, study timelines can be threatened. Delayed dosing may introduce protocol deviations, complicate efficacy assessments, or affect patient retention. For studies involving rare diseases or highly competitive therapeutic areas, these disruptions can have meaningful implications for development timelines and program value.

One of the most common mistakes sponsors make is waiting too long to begin discussing shelf-life extensions. Many organizations initiate extension planning only a few months before product expiration. Unfortunately, shelf-life extensions are rarely simple administrative exercises. Stability testing must be completed and reviewed. Quality organizations must approve the data. Regulatory implications must be assessed. Labeling updates may be required. Depot systems and inventory management systems must be updated. In global studies, implementation may require coordination across multiple countries, languages, and vendors. What initially appears to be a straightforward extension effort can become a complex project spanning several months. Another frequent mistake is treating global inventory as a single supply pool. While inventory reports may show healthy overall stock levels, shelf-life risk often exists at the country level. One region may be at immediate risk while another possesses excess inventory that cannot easily be reallocated. Effective shelf-life management therefore requires detailed, country-specific forecasting that incorporates enrollment projections, depot inventories, distribution lead times, and local implementation requirements. Over-shipment to clinical sites represents another overlooked contributor to shelf-life risk. Many sponsors attempt to minimize stockout concerns by distributing large quantities of inventory to sites. While this approach may appear conservative, it often creates significant inefficiencies. Inventory located at a site is difficult to retrieve, relabel, reallocate, or monitor. Excess stock frequently remains unused at slower-enrolling sites while higher-enrolling sites require additional shipments. The result is fragmented inventory that ages in multiple locations and becomes increasingly difficult to manage.

Managing Shelf-Life Before It Becomes A Crisis

Successful organizations approach shelf-life differently. Rather than viewing expiration dating as a fixed quality attribute, they recognize shelf-life as a strategic asset that must be preserved and actively managed. Every additional month of usable shelf-life provides greater flexibility to accommodate enrollment fluctuations, protocol amendments, shipping delays, customs issues, and unforeseen operational challenges. In this sense, shelf-life becomes a form of supply chain resilience. Effective risk mitigation begins early, ideally during study planning and supply strategy development. Clinical supply, CMC, quality, regulatory affairs, and clinical operations should jointly evaluate expected enrollment timelines, patient treatment duration, packaging configurations, stability data availability, and potential extension opportunities. The objective is to understand not only the initial assigned shelf-life but also how much usable shelf-life will remain throughout the study life cycle.

Treating Shelf-Life As A Supply Chain Asset

Regular governance is equally important. High-performing clinical supply organizations routinely monitor upcoming expiration milestones, stability testing schedules, inventory age profiles, and extension implementation activities. Rather than reacting to imminent expiry dates, they identify and address risks months in advance. Forecasting models incorporate both supply and shelf-life considerations, allowing teams to determine when intervention may be required. Packaging and labeling strategies should also be designed with life cycle management in mind. Inventory often requires shelf-life updates during long-term clinical studies, particularly for investigational products still accumulating stability data. Sponsors that anticipate this reality can implement packaging designs that facilitate efficient relabeling and minimize operational disruption. Small design decisions made early in development can significantly reduce future complexity.

Perhaps the most important lesson from global clinical supply management is that shelf-life should never be viewed as merely a stability outcome. It is an operational resource that requires continuous planning, visibility, and control. The most successful clinical supply organizations recognize that manufactured inventory has value only if it can be legally imported, properly labeled, distributed, stored, and dispensed within the patient's treatment window.

Ultimately, every clinical trial operates against two clocks. One is the study timeline established by protocol milestones, enrollment goals, and regulatory expectations. The second is the shelf-life clock attached to every clinical batch produced. While organizations devote enormous attention to the first clock, it is often the second that creates the most significant operational challenges. For small biopharma companies conducting increasingly global studies, understanding and managing this reality may be the difference between a smoothly executed trial and months of expensive, avoidable supply chain crises. The most valuable clinical inventory is not the inventory sitting in a warehouse. It is the inventory with sufficient remaining life to reach the right patient, in the right country, at the right time. In today's complex global clinical trial environment, preserving that usability has become one of the most critical responsibilities of the clinical supply function.

About The Author:

Joseph G. Oberlander, Ph.D., PMP, is an experienced pharmaceutical development consultant and program manager. His consulting experience ranges from preclinical to Phase 3 programs, across multiple therapeutic areas (oncologic, metabolic, CNS) and drug modalities (NCE, biologics, biosimilars, generics, CGT), at clients ranging from virtual startups to large biopharma, and throughout the drug life cycle (from raw materials sourcing to finished goods use) for drug programs with global operations. His consulting focus includes deep expertise in clinical supply chain strategy and distribution logistics and in analytical and stability program management. In addition, he has significant research experience in neurobiology and is a published author contributing to the understanding of inherent biological sex differences in synaptic physiology and how these differences impact drug effects and deepen our understanding of preclinical disease models.